A Swiss biotech called MetaShape Pharma has presented early animal data suggesting its experimental drug MS 001 could fix some of the biggest problems with popular GLP-1 weight-loss medications like semaglutide. When combined, the two drugs produced greater fat loss than semaglutide alone — but crucially, the animals also gained muscle mass and showed better physical endurance. MS 001 appears to work by increasing energy expenditure and fat burning rather than reducing appetite further. This matters because GLP-1 drugs often cause muscle loss alongside fat loss, which is harmful for long-term health and aging. The findings were presented at the 2026 American Diabetes Association Scientific Sessions. Human trials have not yet begun, so results remain very preliminary.
